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2. Abbreviations 
 
A   attention 
ATC   Anatomical Therapeutic Chemical Classification System 
BDI   Beck Depression Inventory 
BDNF   brain-derived neurotrophic factor 
BP   bipolar 
BOLD   Blood-Oxygen-Level-Dependent 
BOP    Bergen-Oslo Project 
BRMS   Bech-Rafaelsen Melancholia Scale 
C   healthy controls 
CI   confidence interval 
COWAT   Controlled Oral Word Association Test 
Sem   semantic fluency sub-task, Controlled Oral Word Association Test 
Phon   phonological fluency sub-task, Controlled Oral Word Association Test 
DSM-IV   Dagnostic and Statistical Manual of Mental Disorders, 4th edition, 1994 
ECT   electroconvulsive therapy 
EF   executive function 
fMRI   functional magnetic resonance imaging 
GAD   General Anxiety Disorder 
GAF   Global Assessment of Functioning Scale (DSM-IV) 
HADS   Hospital Anxiety and Depression Scale 
HADS-A  Hospital Anxiety and Depression Scale, Anxiety sub-scale 
HADS-D  Hospital Anxiety and Depression Scale, Depression sub-scale 
HUSK   Hordaland Health Study 1997-‘99 
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HAM-D  Hamilton Depression Rating Scale 
ICD-10  International Classification of Diseases, 10th Revision 
ICPC   International Classification System for Primary Care 
IQ   Intelligence quotient  
M   memory function 
MADRS   Montgomery Åsberg Depression Rating Scale 
MCI   mild cognitive deficit 
MDD   major depression 
M.I.N.I  MINI International Neuropsychiatric Interview  
MMSE  Mini-Mental State Examination 
NMDA  N-Methyl-d-Aspartate 
PASAT2  Paced Auditory Serial Addition Test, 2 seconds sub-task 
PASAT3   Paced Auditory Serial Addition Test, 3 seconds sub-task 
PET   positron emission tomography 
R   regression coefficient 
r   Pearson’s correlation coefficient 
rCBF   regional blood flow 
rMDD   remitted or recovered major depression 
ROI   region of interest 
S   psychomotor speed 
SPECT  single photon emission computed tomography 
SSRI   selective serotonin re-uptake inhibitor 
Stroop C/W  Stroop Colour and Word Test, color-word sub-task 
UP   unipolar 
VeM   verbal memory function 
ViM   visual memory function 
VF   verbal fluency 
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WAIS-R  Wechsler’s Adult Intelligence Scale -Revised 
WAIS-R Dsb   Digit Symbol Test from WAIS-R, digit span backward sub-task 
WCST   Wisconsin Card Sorting Test 
Catc   categories completed variable, Wisconsin Card Sorting Test 
Perr   perseverative errors variable, Wisconsin Card Sorting Test 
NPerr   non-perseverative errors variable, Wisconsin Card Sorting Test 
Ftms   failure to maintain set variable, Wisconsin Card Sorting Test 
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4. Introduction 
4.1 Depression  
Depression is a highly prevalent psychiatric disorder (1-3). Life-time prevalence of Major 
Depressive Disorder (MDD) has been reported to be in the range of 7.9 to 17.8% (4, 5). Life-
time cumulative probability of suffering a first episode of MDD has been found to be 27% in 
males and up to 45% in females (6).  
Depressive symptomatology is generally associated with reduced quality of life (7, 8), 
lower level of functioning (7, 9), impaired work capacity (10, 11), and death (12, 13). The co-
morbidity with other psychiatric conditions is high in depression (1, 7, 14-19). And the 
disorder is frequently co-existent with somatic conditions (20). Research during the past 30 
years has made it clear that depression is also associated with lower neurocognitive function 
(21, 22). However, there are several unanswered questions with regard to the association 
between depression and neurocognitive function. 
Depression is regarded as a spectrum disorder (23), with symptoms at all levels found 
in the population (24). The typical course of unipolar depression is depicted in Figure 1. The 
disorder often has a release-relapse course, with recurrent episodes of depression between 
non-symptomatic periods or periods of sub-threshold symptomatology (23, 25). The 
occurrence of one episode is associated with increased risk of further episodes (26, 27).  
Diagnosis of depression is based on anamnestic information and observation of clinical 
characteristics, and not on etiology or evidence of underlying pathobiological changes (26). 
According to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV), diagnosis of a major depressive episode involves the presence of five or more of 
the following symptoms for a period of two weeks or more: 1) depressed mood most of the 
day, 2) diminished interest or pleasure in all, 3) weight loss, weight gain, or decrease or 
increase in appetite, 4) insomnia or hypersomnia, 5) psychomotor agitation or retardation, 6) 
fatigue or loss of energy, 7) feelings of worthlessness or guilt, 8) diminished ability to think or 
concentrate, or 9) recurrent thoughts of death or suicide (28). At least 1) or 2) should be 
present. When no anamnestic information about elevated mood (mania/hypomania) is present, 
MDD is referred to as ”unipolar” (as opposed to “bipolar”).  
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4.2 Neurocognitive function in depression 
4.2.1 Depression is associated with lower neurocognitive function 
Depressed patients’ complaints concerning problems with memory or concentration are well 
known to the experienced physician. The association between depression and neurocognitive 
function has been subject to growing research interest over the past two to three decades. One 
of the main reasons for this interest, is the new examination techniques that have been 
introduced within the fields of neuroimaging, neurophysiology, and genetics. These 
techniques have opened possibilities of linking behavioural data from neuropsychiatry, 
neuropsychology, and cognitive neuroscience to evidence from these new fields. One of these 
new techniques, is functional magnetic resonance imaging (fMRI).  
Previous research has made it clear that depressive symptomatology is associated with 
lower neurocognitive function (21, 29-31). Previous studies have reported deficits in memory 
function (30, 32-36), attention (22, 32, 37-40), executive function (22, 33, 37, 40-44), and 
psychomotor speed (32, 34, 37, 39-41, 45, 46) in depressed patients compared to healthy 
controls.  
In clinical studies performed on younger samples of patients, effect sizes for the 
differences between depressed patients and healthy ones on tests of neurocognitive function 
have frequently been reported to be in the range of half a standard deviation (SD) to one SD of 
the sample mean in favour of the controls (31, 35, 37, 40, 47).   
However, smaller clinical studies may be vulnerable for biases that emerge from the 
many differences that exist between severely ill patients and healthy controls, beyond level of 
depressive symptoms alone. It is obvious that depressed patients included in clinical studies 
are different from depressed subjects who are not included in such studies. Roness et al. 
(2005) recently showed that the majority of persons who suffer from depression do not seek 
professional help for their symptoms (48). So, then patients who are included in clinical 
studies are often those who have sought professional care or have been hospitalised (30, 32, 
35, 49). These patients often have low levels of general functioning (50). They may have more 
co-morbid conditions, use more medication, have lower level of physical activity, higher rates 
of unemployment, and personality-related traits that may influence how they cope in a test 
situation (51-53) compared to patients not included in clinical trials. And the healthy controls 
that the patients are compared with may function better in several areas. These factors can all 
confound the association between depression and performance on tests of neurocognitive 
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function, and, consequently, lead to over-estimation of the effect sizes for the differences in 
neurocognitive function between depressed patients and healthy controls.  
However, two arguments favouring the correctness of estimates of effect from clinical 
studies exist: 1) diagnostic reliability is higher in clinical studies using diagnosis by specialist, 
and 2) in population studies, the most severely ill patients may be under-represented (54). 
Despite these two counter-arguments, the extent to which depression affects neurocognitive 
function is more likely smaller than the findings from clinical studies suggest. 
Information about patients who have not sought help for their psychological problems 
can be found in population-based studies. In order to estimate more correctly the association 
between depression and cognitive function, the association should therefore be examined in 
such samples. This has been done in a few studies (19, 55-58). In these studies, neurocognitive 
tests which are normally used in clinical settings have been used. Several authors have 
reported that higher levels of depressive symptoms are associated with reduced performance 
on measures of neurocognitive function in general population samples (19, 55-58). However, 
in population-based studies the association found between depression and lower 
neurocognitive function has been relatively weak (19, 57).  
When looked at along side one another, it seems reasonable to state that clinical and 
epidemiological study designs provide different kinds of information about the associations 
under investigation. Because they represent different methodology and samples, information 
from both types of designs could be useful to shed light on the associations studied. 
 
4.2.2 Is neurocognitive function relevant for general functioning in 
depression? 
As stated above, depressive symptoms are associated with problems on several dimensions of 
neurocognitive function. This said, it seems crucial to ask the following questions: What are 
the functional consequences of the reduction in neurocognitive function experienced by 
depressed patients? What dimensions of neurocognitive function are relevant for functioning? 
Is lower neurocognitive function associated with impairment of functioning also after recovery 
of the depressive symptoms? And can lower neurocognitive function within a depressive 
episode predict outcome later on?  
It seems like the literature on the association between depression-related 
neurocognitive problems and functional disability is scarce. This is particularly true with 
literature that focuses on long-term effects and rehabilitation. However, previous studies 
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indicate that patients’ problems with coping in everyday situations and in their work-life may 
partly be due to lower neurocognitive function (59, 60). In the present study, attempts will be 
made to clarify some of the questions raised above concerning the association between 
neurocognitive function and general functioning. The predictive value of neurocognitive 
function within a depressive episode for symptomatic and functional recovery will also be 
assessed.  
  
4.2.3 Does neurocognitive function improve upon remission of the depressive 
symptoms? 
As mentioned earlier, it is now generally accepted that major unipolar depression is associated 
with lower performance on tests of neurocognitive function (21, 47). However, it is yet not 
clear, if remission of the depressive symptoms is followed by improvement of neurocognitive 
function in patients who recover from a depressive episode. This question is probably of major 
importance for patients, since they depend on being well-functioning cognitively in order to 
function at work and on other areas of their everyday lives after depression. If neurocognitive 
function normalises after a depressive episode, it can be regarded as a “state”-phenomenon. 
However, if the depression-associated reduction in neurocognitive function persists between 
episodes, it is considered to be a “trait”-factor. Consequently, evidence from previous studies 
investigating neurocognitive function during or after a depressive episode are frequently 
referred to as either supporting the “state”- or the “trait”-hypothesis (61, 62). Within this 
terminology, the term “scaring” is also used. The term “scaring” refers to a change that 
persists after a depressive episode and becomes progressively worse during future episodes 
(63). 
Several authors have reported remission from a depressive episode to be associated 
with improvement in performance on tests of neurocognitive function (64-68). Improvement 
has mainly been reported on measures of verbal fluency (65, 66), attention (65, 67), and 
memory function (65). However, some authors have not found such associations between 
improvement in depression and improvement in tests of neurocognitive function (64, 69, 70). 
A few studies that have compared remitted patients with controls on tasks of verbal fluency 
and memory function have found that patients still perform more poorly than controls (67, 68, 
71). Taking into consideration all these studies, it seems reasonable to conclude that the 
question if, and to what extent, neurocognitive function improves upon remission of 
depression, still is unanswered. 
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Tables 2-4 represent an overview of studies investigating the “state-trait”-question with 
regard to neurocognitive function in depression. These tables are based on literature searches 
performed in the databases MedLine, EmBase, and PsycInfo. Only studies targeting unipolar 
depression and using objective measures of neurocognitive function (neurocognitive tests) 
published after 1985 in English are included. Studies investigating the effect of 
electroconvulsive treatment (ECT) on neurocognitive function, studies which were primarily 
neuroimaging studies, and studies on elderly samples with development of MCI or dementia 
as the target of investigation were excluded from the tables. The studies in Tables 2 through 4 
were scrutinised in terms of methodological approaches to the research questions investigated, 
sample quality and quantity, the aspects of neurocognitive function the tests targeted, and 
results, in addition to the conclusions of the respective authors. This was done in order to 
achieve highest possible consistency of the conclusions and interpretations of results in the 
tables. 
A relevant objection to the results from the studies in the tables is the diversity within 
and between the studies concerning important design- and patient characteristics. The studies 
were heterogeneous with regard to type of patients included, duration of observation, and level 
of depressive rest-symptoms after remission. Yet, they included different diagnostic sub-
groups, age-intervals, and psychotropic medications. Some studies supported the “state”-
hypothesis (Table 3), other studies favoured the “trait”-hypothesis (Table 4), and some studies 
supported both the “state”- and “trait”-models (62, 64, 66, 70-73).  
 
4.2.4 Does longer duration of depression lead to worsening of neurocognitive 
function? 
Studies using computerised tomography (CT), or magnetic resonance imaging (MRI) have 
detected structural changes in the brain in patients with long-standing depression, as compared 
to healthy controls (74-77), or compared to first-episode patients (77). Further, some 
neurocognitive studies have found correlations between longer duration of depression and 
lower performance on tests of neurocognitive function (72, 78, 79). Three hypothesised 
mechanisms for how depression causes neuronal loss and, consequently, reduction in 
neurocognitive function, have been empirically supported by neuroimaging studies or 
neurophysiological studies (80):  
1) Prolonged elevation of serum cortisol, either as part of a stress-response associated 
with depression (81), and/or due to a dysfunction in the feedback regulation in the 
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hypothalamic-pituitary-adrenal axis, may lead to neurotoxic damage to neurons (82-84). This 
hypothesised effect of elevated and dysfunctional regulation of secretion of corticosteroids 
has, in particular, been linked to loss of volume in the hippocampus, and because of this, to 
memory failure (76, 81, 82, 85). In line with this model, Egeland et al. (2005) recently 
reported an association between higher cortisol levels and lower memory function in a work 
using baseline data from the sample in Paper I and II (86).  
2) Loss of glial cells, perhaps partly caused or mediated by glutamat neurotoxicity, has 
also been hypothesised as cause for a possible mechanism of progressive neuronal damage 
(74, 80). The fronto-temporal neuronal circuits may be vulnerable to such cell loss (74, 80). 
Regarding possible localisation of dysfunctions in depression (irrespective of 
underlying cause), it should be mentioned that the frontal or prefrontal cortical areas and the 
frontal-striatal-thalamo-cortical loops associated with these seem to be of particular 
importance in depression. Dysfunctions within these loops have been linked to depressive 
mood and lower neurocognitive function (87-91). The psychomotor slowing frequently 
observed during a depressive episode could be caused by disturbances in the sub-cortical parts 
of these loops (92, 93). These parts are similar to those that are affected in basal ganglia 
disorders.  
3) The neurotrophin brain-derived neurotrophic factor (BDNF), which is involved in 
growth and differentiation of cells, has recently been subject to interest within 
neurophysiological research. BDNF is produced by glial cells, and during exposure to stress, 
BDNF levels are reduced (83, 94). Based on animal studies using induced stress paradigms, it 
has been hypothesised that depression is associated with lower neurogenesis (83, 94). 
Impairment of neurogenesis leads to lower rate of cell repair after toxic damange to neurons. 
In depression, BDNF has particular significance because it has been linked to the increased 
neurogenesis that occurs during administration of antidepressant medication (94-96). In 
relation to antidepressants, the role of N-Methyl-d-Aspartate- (NMDA-) receptors should also 
be mentioned. Activation of these receptors seem to be involved in the long-term potentiation 
important for memory function, and antidepressants act as antagonists on them (96). 
However, several neurocognitive studies have provided results that are contradictory to 
these above described hypothesised models that involve progressive alterations in neuronal 
functioning and worsening of neurocognitive function in depression (64, 66, 68, 70, 97, 98). 
These contradictory studies have not found correlations between estimates of duration of 
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depression and results on tests of neurocognitive function. Thus, it still remains unclear, 
whether recurrent depressive episodes, or long-standing depression, lead to progressive 
worsening of neurocognitive functioning. 
 
4.2.5 Abnormal patterns of regional brain activation in depression 
Regardless of which cerebral dysfunctions it is that underlie the neurocognitive changes 
observed in depression, neurophysiological correlates of these changes must exist. 
Neuroimaging tools, such as functional magnetic resonance imaging (fMRI), Positron 
Emission Tomography (PET), and Single Photon Emission Computed Tomography (SPECT), 
represent unique possibilities of in vivo characterisation of the neurophysiologic mechanisms 
involved in depression. These techniques assess indicators of regional blood flow (rCBF) and 
metabolism in the brain.  
In unipolar depression, functional neuroimaging studies have identified 
neurophysiological abnormalities in several areas of the brain. Studies using Positron 
Emission Tomography (PET) have shown abnormal patterns of regional blood flow and 
glucose metabolism in the prefrontal cortex, in the cingulate gyrus, amygdala, and related 
parts of striatum and thalamus (42, 75, 99-102). In patients with unipolar depression, a 
reduction of rCBF or metabolism in the left dorsolateral prefrontal cortex (Broca’s areas 
(BAs) 9, 46) has been frequently reported in comparisons with healthy controls (93, 103-105). 
A reduction in the anterior cingulate gyrus (BA 24) has also been found (42, 93). Decreased 
activation have been reported in other areas (75, 93, 101). 
However, it still remains unclear as to whether correlates of changes in regional brain 
activation during a depressive episode normalise when the depressive symptoms attenuate. 
Only few functional neuroimaging studies have been longitudinal in design, investigating 
levels of rCBF or metabolism in regions with pathological patterns of activation in 
symptomatic patients after remission of the depressive symptoms. Most of these studies (93, 
102, 105-108), but not all (109) have reported increased metabolism upon remission in areas 
that have shown reduced activation in the symptomatic phase. Upon remission, increases have 
been detected in the left dorsolateral prefrontal cortex (BA 9, 46) (93, 106, 110), and in the left 
anterior cingulate gyrus (Broca 24) (93, 102). However, there is still a long way to go before it 
has been clarified how the patterns of cerebral activation vary when the level of depressive 
psychopathology changes. 
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4.3 Objectives of the study 
The aim of Paper I was to investigate to what extent executive function changes upon 
remission of unipolar major depression. The aims of Paper II were firstly, to investigate if 
dimensions of neurocognitive function improve upon symptom remission in unipolar major 
depression, secondly, to examine if patients who recover completely from the depressive 
episode reach a level of function on these dimensions that is equal to that of healthy controls, 
and thirdly, to investigate if longer duration of depression is associated with lower 
neurocognitive function. The aim of Paper III was to investigate if patterns of regional 
cerebral activation, as measured by functional magnetic resonance imaging (fMRI), change 
during remission from major unipolar depression. The objective of Paper IV was to investigate 
how strong the association between depressive symptomatology and neurocognitive function 
was in an elderly population-based sample. Other aims of the present study not reported in the 
papers were: To investigate if neurocognitive function in major unipolar depression is 
associated with limitations in general functioning, to investigate if neurocognitive function 
predicts change in general functioning when the depressive symptoms attenuate, and to assess 
the predictive value of neurocognitive function within a depressive episode for symptomatic 
recovery later on. 
 
5. Methods 
5.1 Subjects 
The present study presents data from two different samples. Papers I and II are based on a 
clinical sample consisting of thirty younger (mean age 36 years) patients with DSM-IV 
diagnosis of major unipolar depression of recurrent sub-type (111). These 30 were from an 
original baseline sample of 50 patients. They were re-examined with psychometric and 
neurocognitive measures two years after baseline examination in the Bergen-Oslo Project. The 
Bergen-Oslo Project was a collaboration study between several institutions in Bergen and 
Oslo, Norway, starting in 1998. All patients had suffered a minimum of two life-time episodes 
of depression at baseline (mean 3.8). At follow-up, 17 had recovered, and 13 were still 
symptomatic. At inclusion, 20 patients were hospitalised and ten were out-patients. At follow-
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up, all patients who had been hospitalised, had been discharged. Sixteen patients were 
employed or students at baseline. Fifteen were employed or students at follow-up. The other 
patients in the sample were either on sick-leave, received disability pension, or had no income. 
At inclusion, 26 patients were taking psychotropic medication (21 of these used selective 
serotonin re-uptake inhibitors (SSRIs)), at follow-up, 25 were on medication (20 on SSRIs). In 
the studies in Paper I and II, these 30 patients, who were examined twice, were compared to 
50 healthy controls who were examined at baseline. The controls had been recruited through 
an advertisement in the local newspaper, or through personal network. They were comparable 
to the N=50 baseline patient sample with regard to age, gender, education, handedness, and 
intellectual abilities. For further information about background-data, please consult Paper II, 
Table 1, Stordal et al. (2004) (40), or Egeland et al. (2003) (112). 
A sub-sample of nine patients underwent functional magnetic resonance neuroimaging 
(fMRI) scanning at baseline and at follow-up two years later (Paper III). These were compared 
to a sub-sample of healthy controls who were scanned at baseline. fMRI scannings and data-
analyses were made by “the Bergen fMRI-group”, located in Bergen, Norway.  
Paper IV is an epidemiological study based on data from the elderly cohort in the 
Hordaland Health Study 1997-99 (HUSK). The HUSK study was one of the large-scale 
epidemiological studies performed in Norway during the late 1990’s. The study was 
performed as a collaboration by the National Health Screening Service, the University of 
Bergen, and the local health services. In this study, all inhabitants aged 72-74 years old living 
within the city boundaries of Bergen, Norway, were invited to participate in general somatic 
examinations. Out of these, 2,203 subjects agreed to participate in an examination which 
involved tests of neurocognitive function. This amounts to 51% of the total age cohort. 
Twenty-five subjects who performed equal to or below a cut-off of nine points on a modified 
version of the Mini-Mental State Examination, which consisted of the 12 items most sensitive 
to dementia (113), were excluded due to the probable presence of mild cognitive impairment 
(MCI) or dementia. This cut-off corresponds to 23 points on the conventional Mini-Mental 
State Examination (MMSE) (114). The inferential analyses were performed on the 1,930 
subjects who had provided valid answers to the Hospital Anxiety and Depression Scale 
(HADS) (115), and had completed all neurocognitive tests. This sub-sample amounted to 44% 
of the total age cohort. Prevalence numbers for mild and moderate levels of depression were 
found to be 9.3% and 2.2%, respectively, in this sample. These numbers are comparable to 
numbers from other studies recently performed in other Western societies (116-119).  
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5.2 Methods of measurement 
5.2.1 Psychometric instruments 
In Papers I, II, and III, evaluation of diagnosis and level of symptomatology was performed by 
trained psychiatrists. Ratings of symptoms of depression and anxiety were based on self-report 
in Paper IV.  
Three commonly used structured measurement scales were used to measure symptoms 
of depression and/or anxiety. They all represent continuous approaches to levels of symptoms, 
but they can be transformed into dichotomous diagnostic tools by the introduction of cut-offs.  
The 17-item Hamilton Depression Rating Scale (HAM-D) (120) and the 10-item 
Montgomery and Aasberg Depression Rating Scale (MADRS) (121) are both regarded as 
“gold standards” for assessment of depressive symptomatology. Patients included scored equal 
to or above 18 on both the HAM-D and MADRS in Papers I, II, and III. This corresponds to a 
moderate to severe level of depression.  
The third rating instrument, the Hospital Anxiety and Depression Scale (HADS), is a 
structured self-report questionnaire that was developed by Zigmond and Snaith in 1983 to 
identify anxiety and depression among somatic in-patients (115). The instrument has shown 
good case-finding properties in various kinds of samples (122-124), including in general 
population samples (122, 123). It has good psychometric properties with regard to sensitivity, 
specificity, and factor structure in the normal population (122, 123). It should be suitable for 
detection of depression and anxiety in the elderly, since it does not focus on somatic 
symptoms or sleep-problems, which occur frequently in the elderly population. In the 
epidemiological study included in the present work, a cut-off of 8+ was used on the depression 
sub-scale (HADS-D). This corresponds to “mild” degree of depression.  
 
5.2.1.1 Definition of remission and recovery  
No general consensus exists in the literature with regard to definitions and nomenclature of 
remission of symptoms, treatment response, or recovery in depression (25, 125, 126). In the 
present study, any reduction of depressive symptomatology from baseline to follow-up is 
referred to as “remission”, regardless of level and duration of reduction in symptoms. When 
the terms “response” or “responder” are used in studies cited, these are cited as “remission”, or 
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“in remission”. However, in order to avoid misinterpretations, the accurate level of rest-
symptomatology in the studies cited is most often reported (Tables 2-4). 
Generally, the HAM-D is regarded as more sensitive to change than other scales (127).  
To define sub-groups as “recovered” or “non-recovered” according to symptom-status at 
follow-up, a cut-off of 8+ was chosen on the HAM-D in Papers I and II (126). These terms are 
used  consistently through this work. 
 
5.2.2 Neurocognitive function – constructs and measurement 
The cognitive system may be seen as a complex functional system consisting of connected 
sub-systems that correspond to the major parts of what the mind performs (128). While 
cognitive psychology focuses on the theory of how the brain processes, stores, mentally 
manipulates, and expresses information with focus on normal functioning, the field of 
neuropsychology studies the brain-behaviour association in patients with various disorders 
with the purpose of identifying patterns, progression, and neuropsychological correlates of 
cognitive deficits (29, 129, 130). 
Assessment of neurocognitive function is normally done by a battery of neurocognitive 
tests. The battery often includes both pen and paper tests as well as computerised tests. Tests 
are selected to represent different dimensions of neurocognitive functions. After testing the 
patient, the neuropsychologist elaborates performance profiles by comparing the patient’s 
performance on the tests either to other tests he/she has completed, to healthy controls 
comparable with regard to age, gender, level of education, and intellectual abilities (IQ), or to 
norms generated from population samples (129, 130). In research using neurocognitive test 
batteries, significance testing is most often used to detect differences between groups of 
subjects (29). 
 Throughout the present work, the term “neurocognitive” is used when referring to 
cognitive function in general or performance on tests. The term has been chosen because it 
does not refer to any profession or underlying theoretic framework (as opposed to the terms 
“neuropsychological”, “neuropsychiatric”, or “cognitive”). When referring to group 
differences with regard to neurocognitive function, the words “lower” or “reduction” will be 
used (i.e. “neurocognitive function is lower in one group compared to another group”), as 
opposed to the terms “impaired” or “impairment”, which require a defined cut-off for group 
differences (such as one group performing 1.0 or 1.5 SD below another group). Further, the 
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word “dysfunction” has not been used when describing neurocognitive function, since this 
term does not specify directions for associations or group differences (this term is, however, 
used when describing pathobiological mechanisms).  
 
5.2.2.1 Dimensions of neurocognitive function 
In the literature, neurocognitive test measures are often grouped into the following domains of 
function: Attention, memory function, verbal skills, construction (performance), and concept 
formation and reasoning (29, 129, 130). However, it is essential to recognise that these 
constructs are theoretical, although supported by empirical evidence, and that one test measure 
does not necessarily represent one domain of function. Further, it is important to know that in 
order to perform a cognitive task, a composite of mental functions are necessary (29, 129, 
131) and that considerable empirical overlap exists between construct dimensions.  
Because of this, considerable effort was put into the operationalisation of the 
neurocognitive measures in the present study. Operationalisation was based on a priori 
theoretical asssumptions of the essential qualities of the test variables, in combination with 
evaluations of underlying factor structures. Test variables were added up to produce summary 
scales of neurocognitive function. This approach is empirically reasonable because it leads to 
an increase of construct reliability, thus representing a parallell to the approaches used in 
psychiatry, where latent constructs, such as depression, are measured by instruments with 
multiple construct indicators, rather than by asking the one question only: “Do you have 
reduced mood most of the day?”. In Paper II,  the following summary scales of function were 
computed: Attention, verbal memory function, visual memory function, and psychomotor 
speed. In Paper I, a summary scale of executive function was made. Neurocognitive tests with 
literature references are presented in Table 1. 
 
5.2.2.2 Attention 
Attention refers to the processes by which subjects become receptive to and start processing 
incoming stimuli (29, 128, 129). It is a basic cognitive function that is the foundation for all 
test performance. It is closely related to activity rate (speed) and memory function, and it is 
regarded as a function with limited capacity (29, 129). The construct is sub-divided into 1) 
focused or selective attention (referred to as “concentration” in common language), i.e. the 
process of attending to the stimulus that is most important, while suppressing awareness of 
other distracting stimuli (128, 129), 2) sustained attention (vigilance), which refers to the 
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capacity to maintain attentional activity for a period of time, 3) divided attention, which is the 
ability to respond to multiple tasks simultaneously, and 4) alternating attention, which refers to 
the ability to shift focus while performing a task (129). In Paper II, a summary scale of 
attention was created by adding up measures from two frequently used tests that are regarded 
as indicators of attention (132, 133). 
 
5.2.2.3 Memory 
The memory system can be explained by a hypothetical three-stage model that includes 
sensory memory, which very briefly (1-2 seconds) holds large amounts of incoming 
information while selecting and coding information; short time memory (includes immediate 
memory), which is a limited storage stage (7+/-2 bits of information, 30 seconds); and long-
term memory, in which information has been organised and consolidated. This consolidation 
probably happens because of long lasting neurochemical changes at synaptic level. After 
successful encoding, stored information is retrieved by means of recognition or recall of 
learned material. Remembering thus implies both successful encoding and retrieval (129). 
Recently, Baddeley introduced the model of “working memory” to describe the dynamic part 
of short-time memory that is used for active manipulation of information during task 
performance (134). Working memory probably relies on neurophysiological activity in 
particular neuronal networks associated with the prefrontal- and parietal cortices (135-137). In 
Paper II, two scales of memory function were computed by adding up sub-tasks from two 
frequently used tests. One scale measured visual memory function (138).  The other measured 
verbal memory function (139).  
 
5.2.2.4 Executive function 
Executive functions are thought of as higher-level cognitive functions that are involved in the 
control and regulation of lower cognitive operations (129, 140). They have been theoretically 
and empirically linked to functional neuronal circuits involving the prefrontal cortical areas 
(90, 129, 135, 140-142). No overall consensus exists with regard to the operationalisation of 
executive function. As with other dimensions of neurocognitive function, considerable 
conceptual overlap with other dimensions exists. Lezak  has conceptualised it as having the 
following components: volition, planning, purposive action, and effective performance (129) 
(p. 650).  In the present study, an operationalisation has been based on a theoretically and 
empirically funded model, which was introduced by Pennington and Ozonoff in 1996 (143). 
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This operationalisation includes indicators of set-shifting, planning, inhibition, working 
memory, and fluency (132, 133, 144-146).  
 
5.2.2.5 Psychomotor speed 
The rate at which information processing takes place is usually affected by disorders with 
brain dysfunction (129). This is peculiar to disorders involving the sub-cortical structures. 
Psychomotor speed is often assessed by simple reaction time tasks, but it can also be assessed 
by comparing tasks in which speed is essential (timed tasks) with non-speeded tasks (131). 
Slowing may occur at any place in the afferent or efferent systems during task performance 
(129). Considerable overlap with the dimension of attention is inevitable when assessing 
psychomotor speed. In Paper II, psychomotor speed was operationalised by adding up sub-
tasks from two timed tasks (146, 147). 
  
5.2.2.6 Neurocognitive changes in aging 
Because one part of the present study is performed in an elderly sample (Paper IV), it should 
be mentioned that during aging, natural changes in neurocognitive function take place. In 
particular, increasing age is associated with a natural physiologic slowing (129, 148). 
However, memory function also seems to be affected by aging. Some evidence suggests that 
explicit memory is particularly affected, while other aspects of memory function remain more 
preserved (149). Notably, aging also entails problems with vision and hearing; and physical 
impairments such as these may impair neurocognitive test performance (129). 
 
5.2.3 Functional magnetic resonance imaging (fMRI) 
The functional magnetic resonance technique enables voxel-by-voxel mapping of patterns of 
cerebral activation by using magnetic resonance techniques that are sensitive to small local 
magnet-field variations (150). These magnet-field variations are caused by differences in the 
magnetic properties of oxygenated and de-oxygenated blood (referred to as the Blood-
Oxygen-Level-Dependent- (BOLD-) effect). When neurons in particular areas become more 
active in response to sensory stimuli, this leads to increased local metabolism and blood flow. 
Thus, variations in BOLD-magnitude detected in the MR-scanner can be regarded as indirect 
indicators of level of neuronal activation in a particular area. Estimates of neuronal activation 
from the scanning process are subject to excessive statistical processing. In the final step of 
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this processing, estimates from the transformations are projected onto a high resolution 
structural scan of a template brain, thereby creating a statistical “map” of areas (clusters) of 
levels of neuronal activation in the brain. fMRI requires a contrast between two conditions, 
which are typically a “resting state” and an “activated” state, the latter with cognitive or 
emotional stimulus. The “map” of levels of activation during activation is then contrasted with 
the subject’s “map” of levels of activation in the resting state.  
 In the present study, scannings were performed by a 1.5 Tesla Siemens Vision MRI 
system. A “block”-design  method for task presentation was used, in which a mental 
arithmetics task (i.e. stimulus) was presented to the test subject on special LCD-screen goggles 
in runs consisting of “ON-blocks” (stimulus presentation) interrupted by “OFF-blocks” (no 
stimulus presentation). The task used was a visual version of the Paced Auditory Serial 
Addition Test (PASAT). The PASAT is a mental arithmetics task (132). Performing the task 
also involves working memory. In previous studies, similar activation tasks have been 
associated with significant activations in the prefrontal and parietal cortices (135, 136, 151).  
 
5.3 Designs 
In Papers I and II, a longitudinal study design was applied. These papers were based on 
previously detected baseline differences between the depressed patient group and the control 
group (40, 45, 112). In the present study, a follow-up examination of the patient group was 
performed. At follow-up, patients were either partially or totally recovered. Between-group 
comparisons were made with regard to differences in change in neurocognitive function 
between sub-groups of recovered and non-recovered patients (groups defined according to 
symptom status at follow-up). Further, comparisons of recovered and non-recovered patients 
at follow-up with a healthy control group examined at baseline were made in order to assess if 
patients had reached the performance level of controls on neurocognitive tests. In addition to 
the categorical approach to symptoms (i.e. recovered vs. non-recovered sub-groups), analyses 
were performed with a continuous approach to level of depressive symptoms. Data from the 
healthy controls were collected at baseline only. 
Paper III includes a similar design. A sub-sample of the depressed participants and 
healthy controls mentioned above were examined by fMRI. Within-group comparisons were 
made using estimates of levels of regional brain activation between baseline and follow-up. 
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Between-group comparisons were made between patients at baseline, patients at follow-up, 
and healthy controls (scannings of controls performed at baseline only). 
Paper IV is a cross-sectional population-based investigation performed on the birth 
cohorts 1925 to 1927 living in Bergen, Norway. Comparisons between sub-groups scoring 
above or below cut-off for depression and/or anxiety were made. The associations between 
level of or caseness of depression and/or anxiety were explored. 
 
5.4 Statistical procedures 
In Papers I and II, Pearson's correlation coefficients r were calculated for the associations 
between the independent variables and the dependent variables. Independent-samples t tests or 
Mann-Whitney U tests were conducted to assess between-group differences. Indicators of 
neurocognitive function were added up to produce composite scores of neurocognitive 
dimensions. This approach was favoured because it increases construct reliability. It also 
reduces number of statistical comparisons, which is useful when statistical power is limited. 
In Paper III, a three-group, one-way ANOVA model, containing the baseline and 
follow-up investigations of the patients, and the baseline investigation of the control subjects, 
was applied. At follow-up, linear regression analyses were performed in the depressed group 
to investigate if activation within particular regions of interest (ROIs) correlated with level of 
depressive symptomatology. 
In Paper IV, linear regression analyses were performed to assess if depression and/or 
anxiety were associated with neurocognitive function. In analyses with categorical 
independent variables, dummy-variables were made and entered into the linear regression 
model. In a second step, adjustments for possible mediators or confounders were made. 
To investigate to what extent neurocognitive function was associated with level of 
general functioning, linear regression analyses were performed at follow-up in the patient 
sample (N=30) described in Papers I and II. Level of general functioning was assessed using 
the Global Assessment of Functioning (GAF) Scale (28). Neurocognitive operationalisation 
was the same as in Paper II, and the summary scales of neurocognitive dimensions, which 
were computed cross-sectionally at follow-up, were used. These summary scales were entered 
as independent variables and the score on the GAF scale at follow-up was entered as 
dependent variable into the model. In order to adjust for the effect of depressive 
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symptomatology on level of general functioning, HAM-D total score at follow-up was entered 
in a second step. 
In the same sample, the degree to which neurocognitive function within the depressive 
episode predicted improvement in symptomatology and general functioning from baseline to 
follow-up two years later was investigated. Again, summary scales of neurocognitive function 
were computed by adding up test variables in line with the operationalisation used in Paper II. 
This time this was done with baseline scores. These summary scales of neurocognitive 
function were entered into a linear regression model with change in GAF or change in HAM-
D from baseline to follow-up as dependent variables. Change-variables were made by 
subtracting scores at follow-up from scores at baseline. When change in GAF-score was 
entered into the model as dependent variable, the effect of symptomatic improvement on 
change in level of general functioning was adjusted for by entering change in HAM-D from 
baseline to follow-up into the model in a second step.  
Statistical procedures were performed using the SPSS 11.5 (Papers I, II, IV) and the 
SPM99 software package (Paper III). 
 
6. Summary of Papers I to IV 
6.1 Paper I 
Executive function has theoretically been linked to neuronal circuits associated with the 
frontal lobes. These systems may be affected in depression. Previous studies have reported 
that depressed patients perform poorer on tasks regarded as measures of executive function 
compared to healthy controls. To investigate to what extent executive function improved upon 
remission of depressive symptomatology, performance on executive function measures was 
examined on two separate occasions two years apart in patients with recurrent episodes of 
major unipolar depression. At baseline, the patients were moderately to severely depressed, at 
follow-up, they were partly or totally recovered. The main finding was that improvement in 
depression was followed by improvement in executive function. Improvement in depressive 
symptomatology explained 11% of the variance in improvement in executive function from 
baseline to follow-up. No significant difference between recovered patients and healthy 
controls was found. In conclusion, the study provided support for the “state”-hypothesis in 
depression.  
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6.2 Paper II 
Conflicting previous literature has made it difficult to conclude whether remission of 
depression is associated with improvement on different dimensions of neurocognitive 
function. Yet, several hypotheses about long-lasting depression leading to progressive 
worsening of neurocognitive function have been proposed. The aims of this study were 1) to 
examine to what extent neurocognitive function improves upon remission of major unipolar 
depression of recurrent sub-type, 2) to investigate if neurocognitive function returns to normal 
level after recovery from depression (when normal is defined as the performance of healthy 
controls), and 3) to investigate if longer duration of depression is predictive of lower degree of 
improvement in neurocognitive function upon remission. The same sample and time-points of 
measurement as in Paper I were used. Operationalisation of measures of neurocognitive 
function was based on theoretical considerations and factor analysis, and test measures were 
grouped into four dimensions of neurocognitive function: Attention, verbal memory function, 
visual memory function, and psychomotor speed. A significant correlation between 
improvement in depressive symptomatology and change in verbal memory function over time 
was found, both when the association was investigated with categorical and dimensional 
approaches to level of depressive symptomatology. However, the possibility of persistent 
deficits in attention, visual memory function, and psychomotor speed could not entirely be 
ruled out by the study because mean performances in the recovered patients on these 
dimensions were still lower (although non-significantly) than the controls. Duration of 
depression was not predictive of improvement of neurocognitive function. Consequently, the 
study did not support a model in which longer duration of depression leads to progressive 
worsening in neurocognitive function.  
 
6.3 Paper III 
This paper provides a neurophysiological correlate to the findings of improvement in 
neurocognitive function associated with remission of depression in Paper I and II. A sub-
group of patients from the sample used in those papers was examined with fMRI at baseline 
and at follow-up two years later while they were in remission. Scanning was done while the 
patients were performing a mental activation task that has previously been associated with 
increased activation in clusters in the frontal and parietal cortices in non-depressed subjects. 
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The most important finding was that the depressed patients showed significant increases in 
activation in areas related to task performance (in the left posterior cingulate gyrus (BA 31), 
right inferior frontal gyrus (BA 44), and bilaterally in the inferior parietal lobules (BA 40)) 
upon remission of the depressive symptoms. At follow-up, inverse correlations between level 
of depressive symptomatology and level of activation in these clusters were also found. These 
findings indicate that patterns of neuronal activation are altered in depression. The changes in 
activation seem to be related to change in depressive psychopathology. Because studies I and 
II showed improvement in neurocognitive test performance from baseline to follow-up in the 
sample from which the sub-group in Paper III was taken, it is reasonable to infer that the 
changes in level of activation seen in the present study represent a link to the pathobiological 
mechanisms that underlie both the depressive psychopathology and the reduction in 
neurocognitive function associated with it. 
 
6.4 Paper IV 
In this epidemiological study, in a cohort of elderly non-demented patients (aged 72-74 years), 
the previously established inverse association between depressive symptomatology and 
neurocognitive function was confirmed. An apparently inverse association between anxiety 
and reduced neurocognitive performance was explained by adjustment for co-morbid 
depression. Males were more cognitively affected by depressive symptoms than females. The 
inverse association between depressive symptoms and neurocognitive function was found to 
be close to linear, and also present in the sub-clinical symptom range. However, compared to 
effect sizes for the association between depression and neurocognitive function found in 
clinical studies, effect sizes for the association in this population sample were small at all 
levels of depressive symptom-load. In conclusion, the inverse association between depression 
and neurocognitive function was present, however weakly, in the elderly normal population. 
The association was also found at sub-clinical symptom levels. Thus, this inverse association 
between depressive symptoms and neurocognitive function can be regarded as a “normal”-
phenomenon, that is, not only restricted to severely ill patients or to symptom-ranges above 
cut-off for caseness. 
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7. Results concerning neurocognitive function and general 
functioning 
7.1 Neurocognitive function and general functioning 
In the analyses performed to assess to what degree neurocognitive function was associated 
with level of general functioning, a medium-sized correlation was found between the 
psychomotor speed summary scale and the GAF-score at follow-up (R=0.35, R2=0.12, 
beta=0.35, 95% CI= -0.18; 8.40, p=0.060). This marginally significant association between 
lower neurocognitive function and lower level of general functioning was found when patients 
were in remission (mean HAM-D 8.2 (SD 7.6)). After adjustment for the effect of depressive 
symptoms (as measured by the HAM-D) on level of general functioning, the association 
between lower neurocognitive function and lower level of general function was still present 
(R2=0.55, beta=0.24, 95% CI=-0.37; 6.00, p=0.081) and still marginally significant. 
The summary scales of verbal memory function and visual memory function did not 
correlate with GAF-scores at re-testing (r=0.08, and 0.01, respectively (n.s)). A small non-
significant correlation between the summary scale of attention and GAF-score was found 
(R=0.20, R2=0.04, beta=0.20, p=0.293). After adjustment for depressive symptomatology, this 
model still produced non-significant results (R2=0.50, beta=0.06, p=0.681). 
 
7.2 Neurocognitive function as predictor for outcome 
A positive and significant association between psychomotor speed within the depressive 
episode and improvement in GAF-score from baseline to follow-up two years later was found 
(R=0.39, R2=0.15, beta=0.39, 95% CI=0.167; 4.50, p=0.036). After the effect of improvement 
of HAM-D on improvement in GAF-score between baseline and re-test had been adjusted for, 
the association between baseline speed and GAF improvement was marginally significant 
(R2=0.29, beta=0.31, 95% CI= -0.22; 3.9, p=0.077). The other neurocognitive dimensions at 
baseline did not have any predictive value for improvement in general functioning, neither in 
the crude analyses, nor after the effect of change in HAM-D on change in general functioning 
had been adjusted for (crude R=0.16, 0.01, and 0.14 for attention, verbal memory, and visual 
memory, respectively (all p<0.05)).  
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Neurocognitive function within the depressive episode had no predictive value of 
improvement in depressive symptomatology (as represented by change in HAM-D from 
baseline to follow-up) (R in the range 0.01 to 0.23 , all (p<0.05)).  
 
8. Discussion 
8.1 Synopsis of results  
The inverse association between depressive symptoms and neurocognitive function was found 
both in the clinical sample (Papers I and II) and in the population-based sample (Paper IV). In 
Papers I and II, empirical support for the “state”-hypothesis in major unipolar depression was 
found: In depressed patients, performance in several dimensions of neurocognitive function 
improved upon remission. After complete symptomatic recovery, patients’ performance had 
improved to levels that were not significantly different from the performance of healthy 
controls. However, the presence of rest-deficits in neurocognitive function in the patients 
could not be completely excluded by these studies. The studies had limited statistical power, 
and mean test performance in the patient group that had recovered was still not equal to 
controls on several aspects of neurocognitive function. The improvement in depressive 
symptomatology from baseline to follow-up was probably pictured as increased levels of 
activation in certain cerebral regions in the fMRI-study (Paper III). These regions had shown 
reduced levels of activation at baseline when patients were severely depressed. No association 
of duration of depression with improvement of neurocognitive function was found (Paper II). 
In the population-based study, the inverse association between symptoms or caseness of 
depression and neurocognitive function found in an elderly sample was weak, compared to 
effect sizes from previous controlled clinical studies performed on severely depressed elderly 
patients. The inverse association was present at all levels of depressive symptoms, including in 
the lower sub-clinical symptom range typically seen in dysthymia. 
A medium-sized correlation was found between higher psychomotor speed and higher 
levels of general functioning, as measured by the GAF-scale, at follow-up in the sample from 
Papers I and II.  
A positive and significant association between psychomotor speed within the 
depressive episode and improvement in GAF-score from baseline to follow-up was found in 
the same sample. This association was only marginally significant after adjustment for the 
effect of improvement of depression on improvement on GAF-ratings.  
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8.2 How strong is the association between depression and lower 
neurocognitive function? 
8.2.1 Strength of the association in clinical versus population-based samples 
As mentioned earlier, the designs in clinical studies are vulnerable to biases which emerge 
from the many differences between severely ill patients and healthy controls. The population-
based design used in Paper IV should theoretically avoid many of the effects of such biases on 
the association between depression and neurocognitive function. In Paper IV, the effect sizes 
for the group differences between depressed (HADS-D ≥8) were  0.2 SD for ‘S’-task,  0.3 SD 
for m-DST, and 0.3 SD of the sample mean for KOLT in favour of the healthy subjects. These 
effect sizes for the group differences were considerably smaller than those found for the 
association in clinical studies (47, 152). Thus, the effect sizes for the inverse association 
between depression and neurocognitive test performance in the population-based study in 
Paper IV were smaller than findings from clinical studies suggest.  
 
8.2.2 Possible explanations for the discrepancy in effect sizes 
As stated above, the inverse association between depression and neurocognitive function 
found in the population-based study was weaker than findings from previous clinical studies 
have suggested. This discrepancy in effect sizes between clinical and epidemiological studies 
may be caused by different types of biases: If there is a dose-response relationship between 
depression and neurocognitive function, then the clinical studies represent the higher ranges of 
depressive symptoms, and epidemiological studies represent the lower ranges. Therefore, it 
seems reasonable to say that both study designs complement each other when the association 
between these factors is investigated. 
Patients in clinical studies may be different from depressed patients who are not 
included in such studies with regard to a range of characteristics. Examples of factors that can 
potentially confound the associations between depression and neurocognitive function in 
clinical studies are: General level of functioning (59), work status (60), intellectual abilities 
(153), duration of illness, use of medication, sleep disturbances, level of physical activity 
(154), and personality and coping abilities (51-53). About half of the patients in Papers I and 
II were not working and almost all of them were using psychotropic medication. Their ratings 
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of general level of functioning by the GAF-scale (28) suggested that they were severely 
impaired concerning function (see Paper I, Table 2). In addition, the control groups that the 
patient groups were compared to in such studies may be subject to other biases. These controls 
may be healthier and better functioning than the patients they are compared to. The presence 
of such factors mentioned above may lead to inflation of the effect sizes for the differences in 
neurocognitive function between depressed patients and healthy controls in clinical studies.  
In epidemiological studies, however, the most severely ill patients could be under-
represented (54). This may lead to weakening of effect sizes for the associations investigated.   
 
8.3 Effects of antidepressant medication on neurocognitive function 
Investigation of medication effects on neurocognitive function was beyond the scope of the 
present study. However, it should be mentioned, that in the population sample in Paper IV, 58 
of the 1,930 subjects in the sample were taking antidepressant medication. Of these, 29 used 
SSRIs. When the linear regression analyses on the associations between depression and 
neurocognitive function were adjusted for use of antidepressant medication, no change in the 
magnitude of the estimates of effect were found (changes in standardised effect sizes betas 
<2%). This indicates that antidepressant medication did not have impact on neurocognitive 
test results in this sample. The study designs used in Papers I, II, and III, however, did not 
allow for analyses with regard to medication effects. Almost all patients were on psychotropic 
medication. These were of different sub-types, although most patients were taking SSRIs. 
However, previous studies assessing neurocognitive function in medication free depressed 
patients, have also detected significant associations between depression and lower 
neurocognitive function (22, 71, 155). Studies comparing neurocognitive function in patients 
on antidepressants with patients not using antidepressants have not found differences in 
performance on tests of neurocognitive function (47, 70, 156). Because of the results of these 
studies it seems safe to say that the neurocognitive reduction in depression cannot be strongly 
associated with medication use. The use of tricyclic medication is, of course, an exception to 
this, since these agents have sedative effects due to their anticholinergic and antihistaminergic 
properties (83, 157). 
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8.4 The association between neurocognitive function and general 
functioning 
8.4.1 Psychomotor slowing is related to lower general functioning 
In the present study, medium-sized correlations were found between the summary scale of 
psychomotor speed and score on the GAF-scale (r=0.35), and between the summary scale of 
attention and the GAF-score (r=0.23) at follow-up in the patient sample used in Papers I and 
II. These correlations suggest that some dimensions of neurocognitive function are associated 
with lower level of general functioning in depression. Psychomotor slowing was most closely 
associated with lower level of general functioning. This finding may explain why depressed 
patients have problems with tempo-demanding work tasks. 
 
8.4.2  The predictive value of neurocognitive function 
A positive and significant association between psychomotor speed within the depressive 
episode and improvement in GAF was found. Psychomotor speed within the depressive 
episode explained 15% of the total variance in improvement in general functioning from 
baseline to follow-up in the patient sample included in Papers I and II. After the effect of 
improvement in depressive symptoms on GAF-score had been adjusted for, the association 
between baseline speed and GAF improvement was still marginally significant.  
An alternative explanation for this association between slowing and lower tendency to 
functional recovery, could be confounding due to presence of personality traits that are 
associated with more hesitancy and insecurity of the patients in a test situation (51-53). 
Patients who have such personality traits may also have lower potential for functional 
improvement. However, the use of change-variables as dependent variables in the analyses 
referred to above probably made such a confounding effect on the association smaller, because 
the patients then served as his/hers own control in the analyses.  
 
8.5 Discussion of improvement in neurocognitive function 
8.5.1 Results in view of previous findings 
In the present study, significant correlations between improvement in depressive 
symptomatology and improvement in verbal memory function and executive function over 
time were found. These findings were in line with several previous studies that found 
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improvement on single tests regarded as indicators of these constructs: Trichard et al. (1995) 
and Beblo et al. (1999) both found remission of symptoms to be associated with improvement 
of semantic fluency during a short time interval (one month) (66, 158). Tarbuck and Paykel 
(1995) showed that remission was associated with improvement on measures of memory and 
semantic fluency (65). Further, Deuschle et al. (2004) found verbal memory function to be 
improved after recovery (159).  
Contradictory to the findings of the present study, Neu et al. (2001) did not find any 
significant correlation between improvement in depressive symptomatology and improvement 
on tests of fluency and verbal memory during a three-month period of observation (64). Yet, 
also in that study was a significant within-group improvement on semantic fluency and verbal 
memory in the patient sub-group with unipolar depression.  
Williams et al. (2000) reported a significant group difference between remitted patients 
and controls in favour of the controls on a task of short-term memory functioning (67). In this 
study, the follow-up interval was only ten days. Neu et al (2005) reported that remitted 
patients with recurrent episodes of depression still performed lower on verbal memory and 
semantic fluency after remission (9 months follow-up) (68), and Reischies and Neu (2000), 
and Nebes et al. (2000) found no significant group x time interactions between groups of 
remitted patients and healthy controls on measures of attention, verbal memory, visual 
memory, fluency, and psychomotor speed (69, 70).  
 
8.5.2 Possible explanations for conflicting findings with regard to 
neurocognitive improvement 
As shown in Table 3, several previous studies have also supported the “state”-model (65, 67, 
72, 158, 160-162). However, a note of caution should be made with regard to the studies 
comparing remitted patients to healthy controls in Table 3: Small sample sizes make it 
difficult to detect significant differences between remitted patients and controls. As a result of 
this, some studies may have been wrongly classified as supporting the “state”-hypothesis 
instead of the “trait”-hypothesis (Type II error) (67, 72, 160).  
However, as shown in Tables 2 and 4, there have also been several studies that have 
argued against the “state”-hypothesis (62, 64, 66, 68, 70, 71, 73, 155, 156, 163-165). Most of 
these studies were heterogeneous with regard to clinical characteristics of the patients 
included, such as diagnosis, duration of follow-up intervals, level of depressive 
symptomatology at re-test, co-morbidity, and use of medication (64, 66, 68, 70, 155, 156, 
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163). In several of the studies supporting the “trait”-hypothesis, short follow-up intervals (less 
than half a year) in combination with certain degrees of rest-symptomatology at follow-up 
may explain why neurocognitive function was not significantly improved (64, 68-70).  
 
8.5.3 Does neurocognitive function return to “normal” after recovery? 
All the studies shown in Table 2 found rest-deficits in neurocognitive function after remission 
of the depressive symptoms. Similar to this, mean performance in the patient group with 
complete recovery in Paper II was lower (although non-significantly) than the performance of 
the healthy controls on three of the four summary scales of neurocognitive function (Paper II, 
Figure 2). This may indicate that neurocognitive function does not return entirely to normal 
after a depressive episode, given that normal is defined as the performance level of healthy 
controls. Such rest-deficiencies in neurocognitive function have been reported in previous 
studies that compared remitted or recovered patients with healthy controls (62, 66, 71, 72, 163, 
164). Thus, there exists some evidence supporting the “trait”-hypothesis, both in these 
previous studies and in the present study. However, it should be mentioned, that associations 
between depression and neurocognitive function at follow-up in these studies could be 
affected by biases of the kind mentioned in section 8.2.2. 
 
8.5.4 Have patients reached their upper limit of their potential for 
improvement? 
The premorbid level of functioning in the patient group was not known. That is, no estimates 
of the neurocognitive performance of the patient group relative to controls existed, neither 
prior to the actual episode, nor prior to the first depressive episode of depression experienced. 
Thus, even if patients performed lower than controls on several dimensions of neurocognitive 
function after recovery, their performance may actually have returned to their premorbid 
levels. An interesting parallell to this, would be Buist-Bouwman (2004)’s recent study, which 
showed that premorbid levels of different aspects of functioning were lower in subjects who 
later developed depression, and that post-episode functioning returned to these premorbid 
levels (166, 167). If patients’ starting point with regard to neurocognitive function is different 
from healthy controls’, this could either be due to a “trait” feature (either biological or 
psychological), or it could be caused by factors that confound the association between 
depression and neurocognitive function (section 8.2.2.). 
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8.5.5 No predictive value of duration of depression for improvement of 
neurocognitive function 
In our study, duration of illness was not predictive of improvement of neurocognitive function 
during recovery (Paper II). This is in agreement with Neu et al. (2001) (64), and with findings 
from cross-sectional studies that have investigated the association between estimates of 
disease duration and neurocognitive performance in depressed or recovered patients (37, 70, 
79, 98, 168). The findings that estimates of duration of depression did not correlate with 
neurocognitive improvement, suggest that longer duration of disease does not lead to 
progressive deterioration of neurocognitive function. This is contrary to the neurobiological 
models for progressive neuronal damage (“scaring”) presented in section 4.2.4. However, it 
should be kept in mind that the sample studied in Paper II was relatively young (mean age 
35.8), and it is not known how these patients will perform as they age if they continue to 
suffer from recurrent episodes in future.   
 
8.5.6 Conclusion about neurocognitive recovery after depression 
In the present work, there is considerable evidence in favour of the model in which 
improvement of depression is associated with improvement of neurocognitive function. The 
following arguments support the ”state”-hypothesis: 1) Significant correlations between 
improvement in depression and improvement in neurocognitive function from baseline to 
follow-up were found in studies I and II. These associations were consistent both when linear 
and categorical approaches to depressive symptomatology were applied. Further, correlations 
most likely would have been stronger if measurement error in the estimates of depression and 
neurocognitive function had been completely absent. In these correlations, measurement error 
may have been present, both for the estimates of depression and for neurocognitive function, 
at baseline as well as at follow-up. Also, despite our presumption that construct reliability 
increased when the neurocognitive measures were added up to produce composite scales, 
correlations between change in depression and change in neurocognitive function would 
probably have been even larger if construct reliabilites for depression and for the 
neuropsychological constructs were perfect. 2) The patients’ mean performance after total 
recovery was less than half a SD of the sample mean lower than the mean performance of the 
healthy controls. Group differences between the controls and the recovered sub-groups at 
follow-up were statistically non-significant. Both findings indicate that neurocognitive rest-
deficits were small. 3) Given that there exists an association between indicators of neuronal 
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activation visualised by fMRI and depression (Paper III), the change in regional cerebral 
activation upon remission from the depressive episode is a further argument in favour of the 
view that changes in neurocognitive function are reversible.  
However, the present study failed to completely reject the model with persistent 
neurocognitive changes in depression. In Paper II, patients’ performance on several 
dimensions of neurocognitive function did not correlate with improvement of depression; and 
both in Paper I and II marginal (non-significant) rest-deficits in neurocognitive function were 
still present in the recovered patients, compared to controls, at follow-up.  
Yet, based on the three findings initially mentioned in this section, the present study 
gives considerable empirical support for the model in which neurocognitive function 
normalises after depression  (“state”-hypothesis), though the possibility of persistant reduction 
of some aspects of  neurocognitive function (“trait”-effects) is not entirely ruled out.   
  
8.5.7 Changes in patterns of regional brain activation upon remission 
To the best of my knowledge, the study presented in Paper III is the first longitudinal fMRI-
study that uses a cognitive activation paradigm on patients with unipolar depression. However, 
Davidson et al. (2003) used a paradigm in which the participants responded to emotional 
stimuli in a longitudinal study. In their study, significant increases in activation from baseline 
to follow-up eight weeks later were demonstrated in the left anterior cingulate gyrus (169). 
In Paper III, significant within-group changes in activation were demonstrated in the 
depressed group upon remission of the depressive symptoms. The increases in activation were 
detected in the left posterior cingulate gyrus (BA 31), the right inferior frontal gyrus (BA 44), 
and bilaterally in the parietal lobes (BAs 40). The increase in the right inferior parietal lobule 
was seen in the same area that showed reduction in activation relative to healthy controls 
while patients were severely depressed.  
Several PET resting-state studies performed on patients who were depressed at 
baseline and remitted at follow-up have been done (93, 102, 105, 107-110). Most of these 
studies have shown remission of depression to be associated with increase in metabolism in 
the left dorsolateral prefrontal cortex (BAs 9, 46)  (93, 105, 110) or in the left anterior 
cingulate gyrus (BA 24) (93, 106). Similar to our study, Mayberg et al. (2002) and Mayberg et 
al. (1999) found increases in the parietal lobes (BAs 40) upon remission (102, 107). However, 
the recent study by Holthoff et al. (2004) did not find such an increase in activation in these 
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regions upon remission after 12 weeks, but their finding of decrease in activation in 
cerebellum was in line with the present study (109). 
The finding that depressive symptomatology at follow-up correlated with regional 
brain activation in the frontal and parietal lobes, is contradictory to Holthoff et al. (2004) and 
Rose et al. (2005), who did not find such correlations (109, 170). Yet, both those studies 
probably had low statistical power due to small sample sizes; and the analyses were performed 
with restrictions on the scales that measured depressive symptoms (only patients scoring 
within the severe symptom range were included). Therefore, Type II error cannot be excluded 
as cause for the lack of associations in these studies. However, in line with the findings in 
Paper III, several previous studies have found associations between levels of depressive 
symptomatology and activation (171-174). 
Because the stimulation task given during the scanning sessions was a mental 
arithmetics task, which  can also be regarded as a measure of working memory, this change in 
activation in the frontal and parietal lobes should theoretically be related to the improvement 
that was demonstrated on tasks such as the PASAT and the Backward Digit Span sub-task in 
Papers I and II.  
In conclusion, the findings of significant changes in levels of activation in study III 
most likely provide a neurophysiological correlate to the remission of depressive 
symptomatology in Papers I and II. This change in activation may reflect change in the 
neurophysiological mechanisms involved in processing during performance of test tasks.  
9. Methodological considerations 
9.1 General methodological considerations 
9.1.1 Measurement of depressive symptomatology 
Patients included in Paper I and II were diagnosed by trained psychiatrists according to the 
Structured Clinical Interview for DSM-IV axis I disorders - patient edition (SCID I/P, version 
2.0) (111) at inclusion. At follow-up, re-assessment of diagnosis was performed with the 
MINI International Neuropsychiatric Interview (M.I.N.I.) (175). Subjects who no longer 
fulfilled diagnostic criteria were then excluded (two patients had suffered from manic episodes 
and were excluded). In all papers, level of depressive symptomatology was measured by 
commonly used and well validated continuously scaled instruments (115, 120-123, 127). Two 
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out of these are considered as international “Gold-standards” (120, 121). Inter-rater reliability 
for psychometric scales in these papers was assessed at baseline and found to be high (average 
intraclass correlations over 0.80) (112). However, the following considerations about 
assessment of psychiatric caseness and symptom levels  should be discussed: 
 
9.1.1.1 Dimensional versus categorical approach 
In the present work, dimensional approaches to depressive psychopathology have been used 
extensively. Arguments in favour of the dimensional approach are: 1) Psychiatric syndromes 
are in their nature symptom continuums rather than categorical entities. Continuum models 
should be appropriate, both when looking upon one psychiatric condition separately (example: 
depression: low-medium-high levels of symptoms), or when overlap (co-morbidity) between 
syndromes is taken into account (example: depression-schizoaffective disorder-
schizophrenia). 2) The dimensional approach also has the methodological advantage that it 
captures more of the variance in symptomatology than the categorical approach, and 3) it 
avoids errors arising from misclassification of individuals when diagnostic cut-offs are 
introduced on the measurement scales (information bias). Although the present diagnostic 
systems are based on categorical diagnoses, the dimensional approach to psychiatric 
symptomatology is increasingly used in research contexts, and it has been argued that it should 
also be introduced in future versions of the diagnostic systems used by clinicians (176).  
In order to compensate for the low statistical power in Papers I and II, statistical 
analyses were performed on continuously scaled measures. But due to restriction of variances 
on the psychometric scales onto which customary cut-offs had been introduced, the effect 
estimates for the association between depression and lower neurocognitive function may have 
become under-estimated when categorical approaches to levels of depressive symptoms were 
used. This perhaps happened in the comparisons between recovered (N=17) and non-
recovered (N=13) sub-groups in Papers I and II. However, it is important to note that findings 
from the categorical approaches were consistent with findings from the analyses using 
continuous approaches in all associations investigated. 
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9.1.2 Measurement and operationalisation of neurocognitive function 
The construction of the neurocognitive test battery in Papers I and II was based on theory and 
tradition. The test battery was broad, and the tests included are frequently used and well 
validated (132, 133, 138, 139, 144-146, 177). Testing was performed by trained test-
technicians under standardised conditions. Neurocognitive operationalisation in these papers 
was based on theoretic foundations, which were empirically supported by evaluations of 
underlying factor structures and estimates of internal reliability within dimensions. To produce 
composite scales of neurocognitive dimensions of function, single construct indicators (test 
variables) were added up. The composite scales of function were given names in line with the 
consensus that exists among clinicians and in the literature. This said, the following general 
considerations concerning operationalisation of neurocognitive test measures should be 
discussed:  
 
9.1.2.1 Single tests versus composite scales 
Traditionally, clinical neuropsychologists create neurocognitive performance profiles based on 
single test measures, and different test measures are regarded as indicators of different 
dimensions of neurocognitive function, regardless of the empirical overlap between test 
measures and neurocognitive dimensions (29, 129). This approach gives richness of detail, but 
lower reliability. In the present study, construct validity presumably increased when single test 
measures (construct indicators) were added up to produce summary scales of neurocognitive 
dimensions in Papers I and II. This approach also led to lower risk of making Type I errors 
due to multiple comparisons (discussed in 9.1.2.3). However, in Paper IV, only three test tasks 
were available, and lacking the advantage of more information, no summary scale of 
neurocognitive function was made. 
Theoretically, operationalisation of neurocognitive construct indicators can be made on 
three levels of richness of detail: 1) Operationalisation based on single test variables. This 
approach is the conventional approach used in clinical neuropsychology and in research within 
this and related fields. This approach gives richness in detail, but low construct reliability. An 
advantage with analyses based on single tests is that profiles for patients’ performance can be 
made. However, care should be taken when interpreting results based on single variables 
because confidence intervals often are overlapping. Another major concern about this 
approach, is the high risk of committing Type I error when multiple comparisons are 
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performed. In the research literature, it seems to be a general problem that results from studies 
are reported based on findings from analyses on many single tasks, and that findings of 
statistical significance on one or few associations frequently are subject to over-interpretation. 
2) An intermediate level of operationalisation was made in Papers I and II. In this approach, 
dimensions of neurocognitive functions were represented by summary scales consisting of 
several single test variables (construct indicators). This probably gave higher construct 
reliability, less error of measurement, and a tendency for increased correlations in the 
inferential analyses. 3) The third level of operationalisation would involve the computing of 
an “overall” composite scale including all available measures of neurocognitive function from 
the test battery. This approach, however, would lead to complete loss of nuances, and 
probably, no association between depression and the “global” scale of neurocognitive function 
would be detectable. In the present work, an attempt of demonstrating this mechanism was 
made in an exploratory analysis based on the 14 neurocognitive variables of change from 
baseline to follow-up used in the inferential analyses in Paper II. When this “global” 14-items 
composite scale was used as dependent variable, and the linear change in HAM-D score was 
used as independent variable, no significant correlation was found between these scales 
(r=0.23, p=0.122).  
In conclusion, the increase in construct reliability achieved by computing summary 
scales should be regarded as favourable compared to using multiple indicators. However, if 
evaluations about neurocognitive test profiles were the aim of the investigation, analyses on 
single test measures would be useful, provided that statistical power were sufficient.  
 
9.1.2.2 Intercorrelations and redundancy between dimensions 
As mentioned in the introduction, intercorrelation (overlap) between constructs (dimensions) 
of neurocognitive function is considerable. An example of this intercorrelation is shown in 
Table 4 in Paper II, which reports Pearson’s correlation coefficients r between summary scales 
of neurocognitive dimensions (variables of change from baseline to follow-up). Another 
example is given in Figure 2 in the present work, in which each neurocognitive dimension’s 
relative effects on the association between improvement of depression and improvement in 
other neurocognitive dimensions are depicted. Because of the redundancy between 
neurocognitive dimensions, the number of neurocognitive measures used as construct 
indicators was reduced in Paper II. This reduction was achieved by omitting the single task 
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measures with the weakest factor loadings, thereby increasing measurement reliabilities of 
dimensions.  
Because confidence intervals for the neurocognitive single tests were overlapping in 
the analyses in Papers I and II, we were careful about making conclusions about 
neurocognitive improvement profiles based on analyses performed on single test measures. An 
example of this overlap, is shown in Figure 3 in the present work. Figure 3 shows overlapping 
of 95% confidence intervals for single task performances of the recovered and non-recovered 
sub-groups in Paper I. Conclusions about which aspects of neurocognitive function are more 
or less affected in depression should not be made based on analyses of single tests, because 
they are not truly different (overlap of confidence intervals). However, in Papers I and II, the 
results from the analyses performed on single test were presented and discussed with regard to 
neurocognitive profiles. 
 
9.1.2.3 The pitfalls of significance testing 
Most studies that have investigated the difference between patients with psychiatric disorders 
and healthy controls with regard to neurocognitive function have based their findings on 
significance testing (29). If the p-value is significant, most authors conclude that groups are 
different from each other with regard to the test variable(s). However, the p-value does not 
provide any of the following information: 1) What was the magnitude of the difference 
between the groups? 2) Does the difference in means between groups apply to all of the 
people in the group, or just to a sub-group within the sample? 3) Is the statistically significant 
group difference also clinically significant? (29, 178). In light of this, there are two points that 
will be discussed concerning the findings from papers included in the present study:  
1) Significance depend on sample size (178). Significance is more frequent in larger 
samples, even when the magnitudes of associations are the same as in smaller samples. An 
implication of this, is that the possibility of positive findings is larger in larger samples (Type I 
error), and lower in smaller samples (Type II error) (178).  This is easily seen in the present 
study, where Papers I and II, which had low numbers of participants, generated few 
statistically significant findings, and in Paper IV, which was based on a large sample, many p-
values that were below the alpha-level used in Papers I and II were found. But in this paper, 
effect sizes for the associations were still small.  
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2) When multiple comparisons are performed, the risk of false positive findings 
increases (Type I error) (178). For instance, when performing four comparisons, the risk of 
getting one false positive becomes 20% by an alpha-level of 5%. Therefore, care should be 
taken to avoid such false positive findings when performing multiple comparisons. This can 
be done by a priori lowering of the alpha level (Paper IV), or by posthoc adjustment (Paper I).  
In studies I and II multiple construct indicators were added up to produce summary 
scales of neurocognitive function, and the results were based on one (Paper I) or four (Paper 
II) comparison(s) only. Because of this no correction of alpha level was necessary. In addition, 
the use of continuous approaches to the measurements, thereby avoiding restriction of 
variances of the variables, most likely reduced the chances of Type II error due to the low 
statistical power of the studies. Still, in the present work, estimates of effect sizes for the 
associations demonstrated are reported, in addition to whether associations were statistically 
significant or not (p-values). Results were also frequently reported when they were non-
significant. And, the general tendencies and consistencies between findings from different 
methodological approaches were emphasised.  
 
9.1.3 Selection biases 
In all the papers included in the present study, selection biases may have been present. In 
Papers I, II, and III these may have been present in several stages: Firstly, at baseline, because 
patients with complaints about cognitive function may have been more often referred to the 
study than patients without such complaints. And, the severely ill in-patients included in the 
studies may be, in general, different from other patient groups in level of functioning or other 
clinical characteristics. Secondly, selection biases may be present at follow-up because 
patients with disparate levels of depression or cognitive problems may not have been as likely 
to respond to the invitation to participate again. Fischer et al. (2001) previously reported that 
participants lost due to attrition in follow-up studies generally were more severely impaired 
during the baseline hospitalisation, and that males were more often lost than females (179). In 
Papers I and II, patients with longer duration of depression were over-represented at follow-up 
compared to the sub-group that was lost to follow-up. Most likely, this selection bias led to 
inflations of effect sizes for differences between depressed patients and healthy controls (see 
section 8.2.2). It should be noted, however, that there were no detectable differences with 
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regard to important features such as age, gender, education, or intellectual abilities between 
those who were re-tested and those who were lost to follow-up.  
Hansen et al. (2001) previously reported that patients with mental conditions and older 
age are more likely not to participate in health studies (54). In the epidemiological study 
presented in Paper IV, only 51% of the age cohort participated in the neurocognitive 
examination, and after those who had provided non-valid answers had been excluded from the 
data-file, only 44% of the cohort was left for the inferential analyses. This low participation 
rate is one of the major concerns in this paper. Subjects with female gender and lower level of 
education were under-represented in the study sample. As a consequence of these selection 
biases, prevalence of depression and anxiety may have been under-estimated, and variance of 
psychiatric symptomatology could have been restricted. This may again have led to under-
estimation of effect sizes for the association between depression and test performance.  
 
9.1.4 Confounding factors 
In Papers I and II, no significant group differences were found between the recovered and 
non-recovered sub-groups with regard to age, gender, level of education, and level of general 
intellectual abilities when this was tested for. However, many other factors may confound the 
association between depression and neurocognitive function (see section 8.2.2). Examples of 
such factors are general level of functioning, absence from work due to sickness, motivation in 
the test situation, quality of sleep, and use of psychotropic medication or other substances 
(129, 153, 180). For instance, the non-recovered sub-group may, independent of the 
depressive symptomatology itself, in general, have lower level of functioning, less initiative, 
and perhaps also less offensive attitudes to the tasks given in the test situation. All of these 
potential confounding factors may exist independently of depression, or as parts of a 
vulnerability present (perhaps premorbid and independent of the depressive symptomatology), 
which also leads to poorer test performance.  
In Paper IV, considerable effort was made to adjust the inferential analyses for possible 
confounders and mediators of the association between depression and test performance. 
Accurate information about a number of possible confounders was available, such as diagnosis 
(by ICPC- numbers), medication (by ATC-numbers), sleep disturbances, and physical activity. 
All of these factors were adjusted for in the inferential analyses. As expected, large changes in 
effect estimates for the association between depression and neurocognitive function occurred 
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when level of education was entered into the statistical model. However, there may have been 
residual confounding caused by the effect of education or other factors adjusted for in the 
analyses. Further, factors that influence the association between depression and test 
performance not asked for in the test protocol may have been present. For instance, the 
protocol did not include tasks that made it possible to estimate the participants’ general level 
of cognitive abilities (IQ). This is an important confounding factor in associations between 
psychiatric disorders and neurocognitive function (129, 153, 180). 
 
9.2 Further strengths and limitations of papers I to IV 
9.2.1 Papers I and II 
To the best of our knowledge, only one previous study (by Abas et al. (1990) (156), see Table 
4) has had a period of observation similarly long as the study that Papers I, II, and III were 
based on. By using a two year re-testing interval, our study had an advantage if neurocognitive 
recovery takes longer than symptom recovery after a depressive episode. In this timeframe, the 
possible delay in neurocognitive recovery after recovery from depression should be 
eliminated. The longitudinal design of the presemt study was in itself also a strength because 
intra-individual variables of change for depression and neurocognitive function could be 
computed, thus making each subject serve as his/her own “control” in the analyses. By using 
this approach, some of the effect of possible confouders on the association between depression 
and neurocognitive function was possibly avoided  
Other strengths of this study include that the sample was well-characterised and 
homogeneous (only patients with unipolar major depression of recurrent sub-type were 
included). In addition,  30 out of the 50 patients in the original baseline sample were available 
at follow-up, which should be a satisfactory low rate of attrition.  
Re-administration of a neurocognitive test task often leads to improved performance at 
re-testing as a result of learning (181-184). Also, ceiling effects may occur in the second test 
situation. This particularly applies to “one-shot”-tasks such as the Wisconsin Card  Sorting 
Test (WCST) (144, 181, 185). To avoid such test re-test effects, alternate test-forms can be 
distributed at follow-up (64, 65, 70), or learning effects can be assessed with improvement in 
healthy controls as reference. When this was not done in the present study, it was because the 
test re-test interval was so long (two years) that the effect of learning on test performance was 
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probably very minor. In addition, learning effects were most likely equally distributed in the 
recovered and non-recovered sub-groups, since they were equally depressed at baseline. 
 
9.2.2 Paper III 
Theoretically, findings of increase (or decrease) of activation in particular cerebral regions 
during or after depression improvement should be found in regions where 1) patients have 
shown a different level of activation at baseline compared to controls, and 2) healthy controls 
have shown changes in level of activation during stimulus processing (186). In the present 
study, changes of activation were detected in the parietal lobes. However, in the prefrontal 
region, where a significant increase in activation from baseline to follow-up was detected in 
the depressed group, no significant difference in activation was found at baseline in the 
depressed group compared to the controls. The lack of baseline reduction in the depressed 
patients compared to controls in this region, could, however, reflect a mechanism of over-
compensation during task performance. Possibly, the patients “tried harder” to complete the 
neurocognitive task. This increased effort may have lead to more neuronal activation in 
prefrontal areas.  
Another weakness of the present study is that the performance data at the second 
scanning was lost due to a technical error. Thus, the changes in activation at re-test compared 
to at baseline may have been confounded by better test-performance. Yet, it could be argued 
that unless the increase in activation from baseline to follow-up in the depressed group was 
caused by improvement in task performance (as opposed to improvement in depressive 
symptomatology), the loss of information about performance is not relevant for the main 
finding of increased activation over time. Previous studies have shown that level of estimates 
of cerebral activation is not correlated with task performance within depressed groups (151, 
174). Thus, the findings of changes in patterns of activation in the present study can most 
likely be attributed to changes in neuronal activity associated with changes in level of 
depression, rather than test performance.  
 The comparison between the first and second measurement was based on the 
assumption of high test re-test reliability with regard to level of activation at both occasions. 
However, previous reports investigating pre- and post-test reliability have concluded that 
activation data are reliable with regard to this (186, 187). 
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Further limitations of the study were, firstly, that statistical power was low due to low 
number of participants. Secondly, patients were on different medications, which could 
influence neuronal transmission (83), and consequently, patterns of regional brain activation. 
Unfortunately, the design of the study did not allow for assessment of medication effects on 
changes in activation. Finally, it should be mentioned that the assumptions underlying One-
Way ANOVAs with regard to normal distribution of the variances of the dependent variable, 
and independency of test variables (188), may not have been perfectly met. 
   
9.2.3 Paper IV 
In the present study, a self-report measure was used to assess caseness and level of depression. 
Therefore, diagnostic reliability in the analyses was probably lower compared to if diagnosis 
had been made by a specialist using a structured psychometric instrument. The HADS-D (115) 
focuses mostly on features of “anhedonia” in depression, but not on somatic symptoms that 
are related to depression. HADS-A covers anxiety symptoms corresponding to General 
Anxiety Disorder (GAD). This is different from many other “gold-standards”. Therefore, 
some subjects may have been wrongly classified as not suffering from depression or anxiety. 
This may have led to weakening of the associations between depression and/or anxiety and 
lower neurocognitive function.  
Despite this, and despite strong emphasis on psychometrics in measuring psychiatric 
psychopathology and neurocognitive function, error of measurement cannot be ruled out. For 
instance, in the correlations of depression or anxiety with neurocognitive test performances, 
such measurement errors could not be excluded. In these analyses, measurement errors could 
occur both for HADS as well as for the neurocognitive test measures. Measurement errors are 
likely to be random, and most likely resulting in under-estimation of the strength of the 
associations between depression or anxiety and neurocognitive test performance.   
In this paper, the potential presence of un-detected cases with co-morbid dementia or 
mild cognitive deficit (MCI) may have confounded the association between depression and 
neurocognitive function. Depression can be seen as prodrome of or as an early clinical 
manifestation of dementia; and the degree of co-morbidity in these disorders is high (189). 
Although probable cases with dementia or MCI were excluded by an instrument which has 
shown high sensitivity when used as a screening instrument for these conditions (a modified 
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version of the Mini-Mental State Examination (MMSE) (113, 114), there may still have been 
undetected cases included in the analyses on the association between depression and 
neurocognitive function. This may have led to over-estimation of the association. However, 
after further testing using Kendrick’s Object Learning Test (KOLT), which is very sensitive to 
dementia (177), in addition to the modified version of the MMSE to exclude subjects with 
potential MCI or dementia, results regarding the association were not altered. It is therefore 
not likely that the associations found were confounded by the the presence of dementia or 
MCI.  
 
10. Conclusions, implications, and directions for future 
studies 
10.1 Conclusions 
The present study confirmed the presence of an inverse association between depression and 
neurocognitive function. The inverse association between depressive symptoms and cognitive 
function was found to be close to linear, and also present in the sub-clinical symptom range. 
Thus, reduction of neurocognitive function in depression is not a phenomenon restricted only 
to severely depressed patients (in-patients). It can rather be regarded as a “normal”-
phenomenon that also occurs frequently within the normal population. In the normal 
population, it is present in symptom-ranges below diagnostic threshold for depression, i.e. in 
the symptom-ranges often seen in dysthymia. Consequently, it may affect a considerable part 
of the population. Probably it is often seen in primary care settings, where patients with lower-
range depressive symptoms frequently are seen. 
The present study also generated empirical support for a model in which remission 
from depression is followed by improvement in neurocognitive function. However, longer 
duration of depression was not associated with poorer neurocognitive function. And it is 
therefore that the present study does not support a model in which recurrent episodes of 
depressed mood lead to reduction of neurocognitive function. Yet, the present study cannot 
completely exclude the persistence of rest-deficits in neurocognitive function after total 
recovery from the depressive symptoms, as the mean performance in the patient group that 
had become completely well was still marginally below the performance of healthy controls 
(although non-significantly).  
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Remission from depressive symptoms was also associated with changes in patterns of 
neuronal activation as measured by fMRI. These changes were seen in areas in which 
depressed patients previously have shown patterns of activation differently from healthy 
controls. Levels of activation in the patients after they had experienced improvement of 
depression were more similar to the activation of normal controls in the ROIs. This may 
indicate that a normalisation of underlying pathophysiological mechanisms had occured. One 
could speculate that this normalisation could be one of the explanations for the improved 
performance on test tasks after remission in the patients.  
 
10.2 Clinical implications and generalisation of findings 
The finding of an inverse association between depression and neurocognitive function is 
important because this may have implications for patients’ level of functioning on several 
areas in life (59, 60). Clinicians who are responsible for patients who experience problems 
with concentration, memory, and tempo while they are depressed should try to keep the 
following in mind:  
1) Because of the cognitive problems, it may be difficult for the patient to fully benefit 
from intensive psychotherapeutic intervention during the acute phases of episodes of major 
depression. Since these problems seem to improve upon remission of the depressive 
symptoms, such intervention should perhaps be made at a later stage, while the patient is in 
remission.  
2) There exists no evidence suggesting that patients should not receive antidepressant 
medication when they suffer from lower neurocognitive function. The only exception to this 
rule, are tricyclic antidepressants. In the present study, it was shown that use of 
antidepressants did not have a negative impact on neurocognitive function (section 8.3). 
3) Possibly, there exists a delay between improvement in depression and improvement 
in neurocognitive function. An implication of the existence of such a delay is that patients 
need longer sick-leaves, and/or particular arrangements at their work place during the first 
months of work after a depressive episode. It should be recommended that the patient has 
his/her own undisturbed work place, interruptions should be avoided, and work load should be 
tolerable. In particular, it is important to be aware that he/she may be sensitive to tempo-
demanding tasks.  
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4) Clinicians in charge of depressed patients who experience memory and 
concentration problems, should reassure their patients that these problems are most likely 
going to improve when the patient becomes well. Such reassurance could avoid patients’ 
speculations and fear about never “getting normal” cognitively again. 
5) In some psychiatric or neurological disorders, rehabilitation programmes including 
neurocognitive “training” have been attempted (190-192). However, whether such 
programmes are relevant for depression is perhaps debatable because depressed patients are 
probably less affected by problems with cognitive tasks than other patient groups.  
Knowledge generated by Papers I, II, and III can probably be generalised to other 
samples of patients who are severely affected by depression, or to other groups of depressed 
patients with low levels of functioning and need for professional care and medication. 
However, because of biases of participants at inclusion (only severely ill patients were 
selected to participate), findings may to a lesser extent be transferable to patients in 
ambulatory care (e.g. in primary health care), or to the general population. Findings from 
Paper IV are probably generalisable to the kind of elderly patients with lower levels of 
depressive symptomatology typically seen in primary health care settings. However, because 
there may exist confounders that affect the association between depression and neurocognitive 
function exclusively in older age groups, it may be debatable to what extent the findings can 
be transferred to other age groups. 
The studies were not designed in a way that makes it possibly to make inferences about 
causal pathways. Consequently, no conclusions about causal relationships were made. 
However, if one should speculate, it seems appropriate that neurocognitive changes follow 
changes in depressive symptoms, and not vice versa. Also, it seems reasonable to think that 
both the depressive symptoms, the changes in neurocognitive function, and the changes in 
patterns of regional brain activation all are indicators of a common underlying 
pathophysiological dysfunction. 
 
10.3 Directions for future studies 
Studies within genetics, neurophysiology, and functional neuroimaging are going to be central 
in future research on the association between psychiatric disorders and neurocognitive 
function. Researchers using neurocognitive methodology should more often include estimates 
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of biological correlates of depression in their studies in order to better clarify the associations 
between pathobiological changes, depressive psychopathology, and neurocognitive function.  
The following should be taken into consideration in neurocognitive studies of the 
association between depression and neurocognitive function:  
1) Studies should include sufficient numbers of participants in order to avoid problems 
related to low statistical power (multi-center studies). Sufficient power allows for testing of 
hypotheses concerning neurocognitive profiles (whether one dimension of neurocognitive 
function is significantly different from another) and differences between sub-groups.  
2) Longitudinal study designs should be used, since these are more suitable for making 
inferences about causal relationships. In addition, longitudinal designs allow for within-
subject comparisons (as opposed to between-subject comparisons). This reduces the effect of 
group biases on the associations under investigation, and makes it possible to create intra-
individual profiles of change over time for the variables studied.  
3) In order to avoid artificial inflation of effect sizes for the associations between 
depression and neurocognitive function, the associations should also be studied in samples 
from the normal population, and not only by comparing clinical groups with healthy controls. 
Further, an interesting question, which could be answered by using samples from longitudinal 
population studies, is whether premorbid levels of neurocognitive functioning are different in 
individuals who later develop depression compared to in people who do not become 
depressed.  
4) Groups and sub-groups should be well-characterised with regard to 
sociodemographic factors, diagnosis, and clinical characteristics. This allows for adjustment 
for factors that may confound the association between depression and neurocognitive function. 
And it makes it possible to detect the aspects of depression that influences neurocognitive 
function the most. In addition, sub-groups that are impaired with regard to neurocognitive 
function can be characterised and compared to sub-groups of subjects who perform in the 
normal range.  
5) Statistically, a dimensional approach to the variables studied is probably preferable 
to a categorical one, since a dimensional approach avoids misclassification of subjects scoring 
near to cut-off, and because it captures more of the variance of the variables. A consequence 
of this, is that subjects with all levels of depressive symptomatology would be included. Also, 
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conclusions about neurocognitive profiles based on statistically significant findings from one 
or two variables out of many variables tested should be avoided.  
6) Finally, in order to treat and rehabilitate patients optimally, it should be clarified to 
what extent lower neurocognitive function is related to functional disability in depression.  
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13. Errata 
In section 6.4. 
Page 27: ”In this epidemiological study, (a cohort of elderly non-demented patients  
(aged 72-74 years))..” is replaced with “In this epidemiological study, in a cohort of elderly 
non-demented patients (aged 72-74 years)..” 
In section 8.1. 
Page 29: “A medium-sized correlation was found between higher degree of depressive 
symptoms and lower levels of general functioning…” is replaced with “A medium-sized 
correlation was found between higher psychomotor speed and higher levels of general 
functioning..” 
In section 9.1.2.1 
Page 39: “..the high risk of committing Type II error when multiple comparisons are 
performed” is replaced with “..the high risk of committing Type I error when multiple 
comparisons are performed.” 
In section 9.1.4 
Page 43: “In Papers I and II, significant group differences…” is replaced with “In Papers I 
and II, no significant group differences…”. 
In section 9.2.3 
Page 46: “..in the correlations of change in depression with change in neurocognitive test 
performances, such measurement errors could not be excluded. Here such errors could occur 
both at baseline, at re-testing, and for HAM-D as well as for the neurocognitive measures. 
Measurement errors are likely to be random, and most likely resulting in under-estimation of 
the strength of the associations between improvement in depression and improvement in 
neurocognitive performance.” is replaced with “..in the correlations of depression or anxiety 
with neurocognitive test performances, such measurement errors could not be excluded. In 
these analyses, measurement errors could occur both for HADS as well as for the 
neurocognitive test measures. Measurement errors are likely to be random, and most likely 
resulting in under-estimation of the strength of the associations between depression or anxiety 
and neurocognitive test performance.” 
